智通财经APP获悉，2025年4月25日至30日，美国癌症研究协会 (AACR)年会于芝加哥召开。基石药业 (02616) ...

EyeBio’s main asset is Restoret, an intravitreally delivered trispecific antibody that acts as an agonist of the Wnt signalling pathway and is in the phase 1b/2a AMARONE study in DME and ...

The abstracts will be available on the ASCO® website on May 22, 2025 at 5:00 p.m. ET. The full presentation will be available on the Merus website at the start of the session.

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed superior ...

Other companies with T cell engager candidates in the clinic include Boehringer Ingelheim with BI 764532, a CD3xDLL3 bispecific antibody, and Harpoon Therapeutics’ trispecific drug HPN328 ...

The anti-CCP antibody results correlated with RF, but were better than RF as predictor of a more aggressive disease course. After 3 years 5/97 patients had changed anti-CCP status: 2 from negative to ...

Autoimmune thyroid disease (AITD) causes cellular damage and alters thyroid gland function by humoral and cell-mediated mechanisms. Cellular damage occurs when sensitized T-lymphocytes and/or ...

It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has ...

Outer membrane vesicles, biological nanoparticles shed during normal growth by bacteria, have seen significant recent advances in engineering and are thus finding new utility as therapeutic and drug ...